AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31721407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 75
Study 31186020 — intervention group
Group type: EXPERIMENTAL
Intervention: Time needed to harm
Number of subjects: 0
Study 31186020 — intervention group
Group type: COMPARATOR
Intervention: Percent excess risk
Number of subjects: 0
Study 28120485 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 11
Study 28120485 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 30 mg
Number of subjects: 11
Study 28120485 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.375 mg (positive control)
Number of subjects: 11
Study 28120485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (negative control)
Number of subjects: 11
Study 25399551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg twice daily) and trametinib (2 mg once daily)
Number of subjects: 704
Study 25399551 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib (960 mg twice daily)
Number of subjects: 704
Study 25399551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib
Number of subjects: 704
Study 25399551 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib
Number of subjects: 704
Study 23234813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral recombinant human PTH(1‐31)NH(2) 5mg once daily for 24 weeks
Number of subjects: 0
Study 23234813 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous teriparatide
Number of subjects: 0
Study 23234813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21664757 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM intervention (n=26), receiving interactive video-based CRM-training
Number of subjects: 176
Study 21664757 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n=18), receiving an additional ALS-training
Number of subjects: 176
Study 18287453 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm interactive multiplanar reformation (MPR) images
Number of subjects: 96
Study 18287453 — intervention group
Group type: COMPARATOR
Intervention: 3-mm axial images
Number of subjects: 96
Study 17263088 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft drink containing 0.232 g of ginseng and 2 g of ginkgo extract
Number of subjects: 10
Study 12963188 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 25
Study 12963188 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 25
Study 12963188 — intervention group
Group type: COMPARATOR
Intervention: CABG and OPCAB
Number of subjects: 25
Study 10931020 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF)
Number of subjects: 100
Study 10931020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10931020 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 100
Study 10931020 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment with MPFF
Number of subjects: 100
Study 9283511 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (0.4 mg/kg)
Number of subjects: 26
Study 9283511 — intervention group
Group type: EXPERIMENTAL
Intervention: meta‐chlorophenylpiperazine (m‐CPP) (1.0 mg/kg)
Number of subjects: 26
Study 9283511 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 26
Study 7685921 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) and transrectal ultrasonography (TRUS)
Number of subjects: 1284
Study 7685921 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 1284
Study 7685921 — intervention group
Group type: COMPARATOR
Intervention: Prospective randomized trial
Number of subjects: 1284
Study 3106458 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hpGRF‐44 iv administration (1 microgram/Kg bw)
Number of subjects: 23
Study 3106458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple iv administrations (1 microgram/kg bw at 09:30 and 21:30 h for 4 days)
Number of subjects: 23
Study 3106458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sc administration of the same dose at 4‐h intervals by a programmable portable pump
Number of subjects: 23
Study 31429757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nrf2 target gene expression in bronchial epithelium of current smokers
Number of subjects: 89
Study 31429757 — intervention group
Group type: COMPARATOR
Intervention: Nrf2 target gene expression in alveolar macrophages
Number of subjects: 89
Study 31429757 — intervention group
Group type: COMPARATOR
Intervention: Nrf2 target gene expression in nasal epithelium
Number of subjects: 89
Study 31429757 — intervention group
Group type: COMPARATOR
Intervention: Nrf2 target gene expression in peripheral blood mononuclear cells (PBMCs)
Number of subjects: 89
Study 29846100 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + cetuximab for eight cycles followed by cetuximab alone
Number of subjects: 0
Study 29846100 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI + cetuximab
Number of subjects: 0
Study 27583476 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg/d
Number of subjects: 40
Study 24833699 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate in 70% alcohol
Number of subjects: 750
Study 24833699 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone iodine in 70% alcohol
Number of subjects: 750
Study 22489255 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2.0 mg)
Number of subjects: 36
Study 22489255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20222968 — intervention group
Group type: EXPERIMENTAL
Intervention: Medifast's meal replacement program (MD)
Number of subjects: 90
Study 20222968 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, food‐based diet (FB)
Number of subjects: 90
Study 20222968 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 90
Study 18669979 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg/day + fenofibrate 160 mg/day
Number of subjects: 611
Study 18669979 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg/day
Number of subjects: 611
Study 18669979 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg/day
Number of subjects: 611
Study 18669979 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 611
Study 16394908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tPA and heparin
Number of subjects: 18
Study 16394908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial tPA
Number of subjects: 18
Study 12873939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 210 microg/kg
Number of subjects: 53
Study 12873939 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 53
Study 10567287 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 214
Study 10567287 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 214
Study 10567287 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 214
Study 10567287 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 214
Study 10567287 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and Angioplasty
Number of subjects: 214
Study 8638025 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study 8638025 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 0
Study 8638025 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 0
Study 8638025 — intervention group
Group type: COMPARATOR
Intervention: Empiric amiodarone therapy
Number of subjects: 0
Study 8638025 — intervention group
Group type: COMPARATOR
Intervention: Type-I antiarrhythmic drugs
Number of subjects: 0
Study 8638025 — intervention group
Group type: COMPARATOR
Intervention: Mixed group of antiarrhythmic drugs
Number of subjects: 0
Study 1887968 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1.25 micrograms/kg
Number of subjects: 30
Study 1887968 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.625 micrograms/kg
Number of subjects: 30
Study 1887968 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 6693150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baumanometer
Number of subjects: 72
Study 6693150 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriosonde 1216
Number of subjects: 72
Study 6693150 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiometrics SR‐2
Number of subjects: 72
Study 6693150 — intervention group
Group type: EXPERIMENTAL
Intervention: Random‐zero
Number of subjects: 72
Study 31738072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for AUD, duration: 12 weeks
Number of subjects: 92
Study 29551654 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week diabetes education program
Number of subjects: 29
Study 26990318 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 20
Study 26990318 — intervention group
Group type: COMPARATOR
Intervention: SST
Number of subjects: 20
Study 24446216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fufang Xuelian Burn Ointment (FXBO) plus common burn wound therapy
Number of subjects: 240
Study 24446216 — intervention group
Group type: COMPARATOR
Intervention: Common burn wound therapy
Number of subjects: 240
Study 22390186 — intervention group
Group type: EXPERIMENTAL
Intervention: HP‐hMG
Number of subjects: 127
Study 22390186 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 127
Study 20499223 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence (n = 30)
Number of subjects: 61
Study 20499223 — intervention group
Group type: COMPARATOR
Intervention: Parental absence (n = 31)
Number of subjects: 61
Study 17493470 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg/day)
Number of subjects: 32
Study 17493470 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day)
Number of subjects: 32
Study 18159246 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 958
Study 18159246 — intervention group
Group type: COMPARATOR
Intervention: Non-exclusive breastfeeding (non-EBF)
Number of subjects: 958
Study 14667432 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy challenge
Number of subjects: 25
Study 14667432 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study 10689269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipper hypertensive patients
Number of subjects: 76
Study 10689269 — intervention group
Group type: COMPARATOR
Intervention: Dipper and nondipper groups
Number of subjects: 76
Study 10689269 — intervention group
Group type: COMPARATOR
Intervention: Dippers and nondippers
Number of subjects: 76
Study 10689269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipper patients
Number of subjects: 76
Study 9288477 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison stimulus with varying loudness
Number of subjects: 0
Study 9288477 — intervention group
Group type: COMPARATOR
Intervention: Reference stimulus with fixed pulse rate
Number of subjects: 0
Study 8472519 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg tablet of ST‐679
Number of subjects: 0
Study 8472519 — intervention group
Group type: COMPARATOR
Intervention: 600 mg capsule of ST‐679
Number of subjects: 0
Study 3082297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nasogastric feeding
Number of subjects: 100
Study 3082297 — intervention group
Group type: COMPARATOR
Intervention: Continuous nasoduodenal feeding
Number of subjects: 100
Study 31926340 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Number of subjects: 170
Study 31926340 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 40 mg
Number of subjects: 170
Study 31926340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 31926340 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg and 40 mg
Number of subjects: 170
Study 31413542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5‐5 mg/day
Number of subjects: 40
Study 31413542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28851434 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox‐intervention (implemented for 6 weeks)
Number of subjects: 2438
Study 28851434 — intervention group
Group type: EXPERIMENTAL
Intervention: High teachers process evaluation score
Number of subjects: 2438
Study 28851434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low teachers process evaluation score
Number of subjects: 2438
Study 28851434 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' process evaluation score (low, medium, high)
Number of subjects: 2438
Study 25743737 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame
Number of subjects: 61
Study 25743737 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 61
Study 25743737 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study 22757665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540 nm non-ablative fractional laser (NAFL) treatment, 4 treatments at monthly intervals
Number of subjects: 24
Study 22757665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540 nm non-ablative fractional laser (NAFL) treatment
Number of subjects: 24
Study 22757665 — intervention group
Group type: COMPARATOR
Intervention: Control side (untreated)
Number of subjects: 24
Study 22757665 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFL treatment
Number of subjects: 24
Study 21576636 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg orally twice a day) plus erlotinib (150 mg orally daily)
Number of subjects: 168
Study 21576636 — intervention group
Group type: COMPARATOR
Intervention: placebo plus erlotinib (150 mg orally daily)
Number of subjects: 168
Study 21576636 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib/erlotinib
Number of subjects: 168
Study 21576636 — intervention group
Group type: COMPARATOR
Intervention: placebo/erlotinib
Number of subjects: 168
Study 19589270 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 84
Study 19589270 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy (AH)
Number of subjects: 84
Study 16466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) subjects
Number of subjects: 29
Study 16466589 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-MCI subjects)
Number of subjects: 29
Study 14586588 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure (75 dBA)
Number of subjects: 9
Study 14586588 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor exposure (furfurylmercaptan)
Number of subjects: 9
Study 14586588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure (noise + odor)
Number of subjects: 9
Study 14586588 — intervention group
Group type: COMPARATOR
Intervention: Combined exposure vs. single exposures
Number of subjects: 9
Study 10711927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (24 mg daily)
Number of subjects: 29
Study 10711927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15321287 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (5 mg)
Number of subjects: 60
Study 15321287 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine patient‐controlled analgesia (PCA)
Number of subjects: 60
Study 15321287 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60
Study 15321287 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine and Intravenous morphine patient‐controlled analgesia (PCA)
Number of subjects: 60
Study 8242290 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 60
Study 8242290 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 60
Study 3899048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (mean dosage, 141 mg/day)
Number of subjects: 19
Study 3899048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30204919 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-management program
Number of subjects: 289
Study 30204919 — intervention group
Group type: COMPARATOR
Intervention: Online disease education program (control)
Number of subjects: 289
Study 29790278 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose 4-L polyethylene glycol (4-SD)
Number of subjects: 187
Study 29790278 — intervention group
Group type: COMPARATOR
Intervention: Routine, morning-only 2-L polyethylene glycol (2-MO)
Number of subjects: 187
Study 27240140 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers (WW)
Number of subjects: 300
Study 27240140 — intervention group
Group type: COMPARATOR
Intervention: Nutrition Education (NE)
Number of subjects: 300
Study 25261141 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking frame with a porter and a nurse from the postanesthesia care unit to the general ward
Number of subjects: 22
Study 25261141 — intervention group
Group type: COMPARATOR
Intervention: Transported in their beds
Number of subjects: 22
Study 22320902 — intervention group
Group type: EXPERIMENTAL
Intervention: HVP (soluble highly viscous polysaccharide)
Number of subjects: 54
Study 22320902 — intervention group
Group type: COMPARATOR
Intervention: Control (skim milk powder)
Number of subjects: 54
Study 20566719 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus graft
Number of subjects: 164
Study 20566719 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone graft
Number of subjects: 164
Study 20566719 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstructions (<5 months)
Number of subjects: 164
Study 20566719 — intervention group
Group type: COMPARATOR
Intervention: Later reconstructions (>5 months)
Number of subjects: 164
Study 20566719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without medial meniscal surgery
Number of subjects: 164
Study 20566719 — intervention group
Group type: COMPARATOR
Intervention: Patients with medial meniscal surgery
Number of subjects: 164
Study 20566719 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical functioning in Short Form-36 for early-reconstructed patients
Number of subjects: 164
Study 20566719 — intervention group
Group type: COMPARATOR
Intervention: Physical functioning in Short Form-36 for later-reconstructed patients
Number of subjects: 164
Study 16996618 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Dilatation (BD)
Number of subjects: 37
Study 16996618 — intervention group
Group type: COMPARATOR
Intervention: Bicanalicular Silicone Tube Intubation (STI)
Number of subjects: 37
Study 14766688 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 1 g
Number of subjects: 300
Study 14766688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (40 mg)
Number of subjects: 300
Study 14766688 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 300
Study 11575338 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 11575338 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 90
Study 11575338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study 11575338 — intervention group
Group type: COMPARATOR
Intervention: Lash reflex
Number of subjects: 90
Study 11575338 — intervention group
Group type: COMPARATOR
Intervention: Loss of grip of a small metal cylinder
Number of subjects: 90
Study 11575338 — intervention group
Group type: COMPARATOR
Intervention: Loss of voluntary finger tapping
Number of subjects: 90
Study 11575338 — intervention group
Group type: COMPARATOR
Intervention: Loss of postural tone in an outstretched arm
Number of subjects: 90
Study 9763047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 500
Study 9763047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 8186139 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg daily for 4 weeks
Number of subjects: 83
Study 8186139 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg daily for 4 weeks
Number of subjects: 83
Study 8186139 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 83
Study 3110248 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP), 200 micrograms twice daily
Number of subjects: 38
Study 3110248 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG), 2 mg four times daily
Number of subjects: 38
Study 3110248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (BDP and SCG)
Number of subjects: 38
Study 3110248 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) in the second period
Number of subjects: 38
Study 29880873 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 29
Study 29880873 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study 27242121 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg zinc sulphate dispersible tablet, once daily for six months
Number of subjects: 55
Study 27242121 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily for six months
Number of subjects: 55
Study 23582750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mahjong
Number of subjects: 110
Study 23582750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 110
Study 23582750 — intervention group
Group type: COMPARATOR
Intervention: Control (simple handicrafts)
Number of subjects: 110
Study 22958612 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in overweight/obese individuals
Number of subjects: 601
Study 22958612 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in individuals with metabolic syndrome
Number of subjects: 601
Study 22958612 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 601